Paul Goodwin, science director, GE Healthcare Life Sciences, discusses how 3D bioprinting could advance precision health in the future.
In the US alone, there are over 120,000 people awaiting organ transplants annually and fewer than 15,000 donors. What if we could manufacture organs from cells and essentially solve this shortage without any donor necessary? Perhaps ambitious. But perhaps possible.